ライフサイエンスコーパス: idarucizumab

1 ate [4F-PCC]; 525, andexanet alfa [AA]; 340, idarucizumab).

2 l-vein bleeding time, which were reversed by idarucizumab.

3 atran-treated nondialysis patients receiving idarucizumab.

4 n or dabigatran acylglucuronide, followed by idarucizumab.

5 their intended intervention after receiving idarucizumab.

6 Idarucizumab (1 g, 2 g, or 4 g 5-min infusion, or 5 g pl

7 m analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B).

8 for dTT was 1.01 with placebo, 0.26 with 1 g idarucizumab (74% reduction), 0.06 with 2 g idarucizumab

9 idarucizumab (74% reduction), 0.06 with 2 g idarucizumab (94% reduction), 0.02 with 4 g idarucizumab

10 idarucizumab (94% reduction), 0.02 with 4 g idarucizumab (98% reduction), and 0.01 with 5 g plus 2.5

11 98% reduction), and 0.01 with 5 g plus 2.5 g idarucizumab (99% reduction).

12 rsal of Dabigatran Anticoagulant Effect With Idarucizumab), a prospective, multicenter, open-label st

13 Idarucizumab, a humanized monoclonal antibody fragment,

14 Idarucizumab, a monoclonal antibody fragment, binds to b

15 Idarucizumab, a monoclonal antibody fragment, was develo

16 ts were to receive a 5-g dose of intravenous idarucizumab, administered as 2 bolus infusions of 2.5 g

17 ombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoa

18 dilute thrombin time was 100% within 4 h of idarucizumab administration, and over 98% of patients ac

19 We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran

20 Idarucizumab, an antibody fragment, was developed to rev

21 he direct oral anticoagulant reversal agents idarucizumab and andexanet alfa in US hospitals.

22 o determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagula

23 5 g plus 2.5 g idarucizumab groups (nine to idarucizumab and three to placebo in each group), and 11

24 ed into the 4 g idarucizumab group (eight to idarucizumab and three to placebo).

25 rospective, multicenter, open-label study of idarucizumab, and were followed up for 90 days for prima

26 ation within 4 hours after administration of idarucizumab as measured by the dabigatran-specific assa

27 f 202 patients in this group received 5 g of idarucizumab before surgery or procedures.

28 Idarucizumab completely reversed the anticoagulant effec

29 Idarucizumab completely reverses dabigatran in >98% of p

30 At a concentration of 1 uM, idarucizumab demonstrated significantly greater reversal

31 This study aimed to evaluate whether idarucizumab differentially reverses the anticoagulant e

32 ere no serious adverse safety signals due to idarucizumab dosing.

33 These findings indicate that idarucizumab exerts a more potent reversal effect on dab

34 Idarucizumab facilitates management of patients requirin

35 Idarucizumab for reversal of dabigatran had an anticoagu

36 roved humanized monoclonal antibody fragment idarucizumab for reversing the effects of dabigatran, th

37 ability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects o

38 ide insights into the efficacy and safety of idarucizumab for urgent dabigatran reversal in patients

39 ch group), and 11 were enrolled into the 4 g idarucizumab group (eight to idarucizumab and three to p

40 and hot flushes), one in the 5 g plus 2.5 g idarucizumab group (epistaxis); one receiving placebo (i

41 ported in seven participants: one in the 1 g idarucizumab group (infusion site erythema and hot flush

42 into each of the 1 g, 2 g, or 5 g plus 2.5 g idarucizumab groups (nine to idarucizumab and three to p

43 Idarucizumab immediately and completely reversed dabigat

44 Idarucizumab in equimolar dose prevented excess hematoma

45 ients in RE-VERSE AD (Reversal of Effects of Idarucizumab in Patients on Active Dabigatran), the exte

46 Idarucizumab is a monoclonal antibody fragment that bind

47 Idarucizumab is available as an antidote to rapidly reve

48 Dabigatran and idarucizumab, its reversal agent, are renally cleared.

49 rothrombin complex concentrates (n = 2,688), idarucizumab (n = 1,111), or andexanet (n = 936).

50 rsal of Dabigatran Anticoagulant Effect With Idarucizumab; NCT02104947).

51 Idarucizumab normalized the test results in 88 to 98% of

52 n within 4 hours after the administration of idarucizumab, on the basis of the determination at a cen

53 n within 4 hours after the administration of idarucizumab, on the basis of the diluted thrombin time

54 The use of specific reversal agents (ie, idarucizumab or andexanet alfa) prior to thrombolysis is

55 mly assigned within groups in a 3:1 ratio to idarucizumab or placebo using a pseudorandom number gene

56 f 4-factor prothrombin complex concentrates, idarucizumab, or andexanet for reversal of severe DOAC-a

57 agent (eg, prothrombin complex concentrates, idarucizumab, or andexanet-alpha) prior to an emergent o

58 Thus, idarucizumab prevents excess intracerebral hematoma form

59 In emergency situations, idarucizumab rapidly, durably, and safely reversed the a

60 Idarucizumab showed a rapid and complete reversal of dab

61 In more extensive ICH, idarucizumab significantly reduced mortality.

62 The median time from the first vial of idarucizumab to surgery or procedures was less than 2 ho

63 These phase 1 results show that idarucizumab was associated with immediate, complete, an

64 tudy to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant